Iodine-131 labelled octreotide: not an option for somatostatin receptor therapy.
Gamma-emitting radiopeptides are useful for scintigraphy of tumours on the basis of receptor binding. Likewise, beta-emitting radiopeptides may be used in radionuclide therapy of such tumours. As iodine-131 suggested to be suitable for this purpose, experiments were performed using three somatostatin analogues, in which the effects of coupling of a therapeutic dose of 131I to such peptides were investigated. This study deals with the radioiodination of very small amounts of peptide on a therapeutic scale, the required purification procedures after radioiodination, and the influence of high beta fluxes from 131I on a peptide during radioiodination and purification. Based on the regularly used therapeutic doses of 131I in cancer treatment and our previous experience with [111In-DTPA-D-Phe1]-octreotide, it was assumed that a minimal effective therapeutic dose of 3.7 GBq 131I has to be coupled to a maximum of approximately 100 microg peptide, representing only a slight excess of peptide over 131I. This contrasts with non-peptide radiopharmaceuticals in which high compound to radionuclide ratios are usually used. Labelling at low peptide to radionuclide ratios (low labelling yields) results in the formation of di-iodinated compounds, whereas at high peptide to radionuclide ratios (high labelling yields) mono-iodinated products of low specific activity are formed. Thus, after radioiodination the desired mono-iodinated peptide has to be separated from unreacted iodide, and from di-iodinated and unreacted peptide, as both compounds compete for the receptors. Possible radiolysis of the peptide during labelling and separation steps were investigated by irradiating 30 microgram unlabelled peptide with 370 MBq 131I in a small volume. The peptide composition of the incubation mixtures was investigated by high-performance liquid chromatography after irradiation for 30 min to 24 h. The results showed that the peptide was degraded with a half-life of less than 1 h. During the preparation of a real therapeutic dose (at much higher beta-flux) the peptide will be degraded even faster during the various steps required. In conclusion, intact mono-iodinated 131I-labelled somatostatin analogues for peptide receptor therapy will be difficult to obtain.
Bakker
W H
WH
Department of Nuclear Medicine, University Hospital Dijkzigt and Erasmus University Medical School, Rotterdam, The Netherlands.
Breeman
W A
WA
van der Pluijm
M E
ME
de Jong
M
M
Visser
T J
TJ
Krenning
E P
EP
D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000138:chemical synthesis / Q000627:therapeutic use*; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007553:Isotope Labeling; D015282:Octreotide / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000627:therapeutic use*; D004369:Pentetic Acid / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000627:therapeutic use; D017481:Receptors, Somatostatin; D013004:Somatostatin / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000627:therapeutic use
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D007457:Iodine Radioisotopes; D017481:Receptors, Somatostatin; C045210:3-Tyr-octreotide; C071632:SDZ 215-811; C051458:vapreotide; D013004:Somatostatin; D004369:Pentetic Acid; D015282:Octreotide